direct anticoagulant

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Non-Small Cell Lung CancerStrokeAtrial FibrillationHip FractureVenous ThromboembolismHead Injury

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

1

direct anticoagulant

Bayer

Phase 3

122

Yervoy

Bristol-Myers Squibb

Preclinical

313

Gemzar

GGynecologic Oncology Group

Preclinical

724

Lenvima

Eisai

Preclinical

65

Vizimpro

Pfizer

Preclinical

46

Gilotrif

Boehringer Ingelheim

Preclinical

127

Ofev

Boehringer Ingelheim

Preclinical

78

Immunotherapy

Bristol-Myers Squibb

Preclinical

129

PD-1 Inhibitor

Johnson & Johnson

Preclinical

210

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

—Show 21 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Stroke3 trials

An Observational Cross-sectional Study Evaluating the Sociodemographic and Clinical Characteristics of Patients Diagnosed With NVAF With a Risk of Stroke or Systemic Embolism, Who Are on Treatment to Adequately Control Their Coagulation and Treated in Primary Care Centres

Completed·Bayer··NCT02470767·792 enrolled

DOAC or VKA in Patients With AF and Stroke While on DOAC - a Pilot Trial

Not yet recruiting·PPopulation Health Research Institute·Phase 1·NCT07011095·100 enrolled

OPTIMAS: OPtimal TIMing of Anticoagulation After Acute Ischaemic Stroke : a Randomised Controlled Trial

Active, not recruiting·UUniversity College, London·N/A·NCT03759938·3,648 enrolled

Low Molecular Weight Heparin1 trial

Low Molecular Weight Heparin vs Direct Oral Anticoagulant After Bariatric Surgery

Active, not recruiting·—·Phase 1·NCT06913595·100 enrolled

Anticoagulant1 trial

Periprocedural Direct Oral Anticoagulant Management

Completed·FFundación para la Investigación del Hospital Clínico de Valencia··NCT03182218·1,100 enrolled

Venous Thromboembolism1 trial

Rivaroxaban in Elderly Chinese Venous Thromboembolism Patients

Recruiting·PPeking Union Medical College Hospital··NCT06194617·300 enrolled

Anticoagulation1 trial

Anticoagulation Therapy in Non-device-related Intra-cardiac Thrombus

Active, not recruiting·—·Phase 3·NCT05825573·340 enrolled

5 more indications

Atrial Fibrillation1 trial

An Observational Cross-sectional Study Evaluating the Use of Re-sources and the Sociodemographic and Clinical Characteristics of Patients Diagnosed With Non-valvular Atrial Fibrillation With a Risk of Stroke or Systemic Embolism on Anticoagulant Therapy and Treated in Primary Care Centers

Completed·Bayer··NCT02559232·247 enrolled

Head Injury1 trial

Mild Head Injury, Antiplatelets, and Anticoagulants

Completed·FFondazione Policlinico Universitario Agostino Gemelli IRCCS··NCT04741334·2,127 enrolled

Uterine Bleeding1 trial

A Study of Severe Uterine Bleeding Following Exposure to Direct Oral Anticoagulants

Completed·Johnson & Johnson··NCT04394234·961,985 enrolled

Hip Fracture1 trial

Hip Fracture Surgery Arterial and Venous Thrombotic Events Prevention

Not yet recruiting·MMcMaster University·Phase 3·NCT07228663·100 enrolled

Carcinoma, Non-Small-Cell Lung1 trial

A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients With Advanced or Metastatic Solid Tumors Including EGFR-mutated Non-Small Cell Lung Cancer

Recruiting·Johnson & Johnson·Phase 2·NCT05498428·520 enrolled

Details

Drug Info

Related News